NewLink Genetics (Ebola vaccine) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

NewLink Genetics (Ebola vaccine) General Information

Description

Portfolio of Ebola vaccine. The vaccine candidate, called rVSV-EBOV, was originally developed by the Public Health Agency of Canada. It is currently being evaluated in phase-I clinical trials.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Acquirer
Corporate Office
  • Ames, IA
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NewLink Genetics (Ebola vaccine) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore NewLink Genetics (Ebola vaccine)‘s full profile, request access.

Request a free trial

NewLink Genetics (Ebola vaccine) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore NewLink Genetics (Ebola vaccine)‘s full profile, request access.

Request a free trial

NewLink Genetics (Ebola vaccine) FAQs

  • Where is NewLink Genetics (Ebola vaccine) headquartered?

    NewLink Genetics (Ebola vaccine) is headquartered in Ames, IA.

  • What industry is NewLink Genetics (Ebola vaccine) in?

    NewLink Genetics (Ebola vaccine)’s primary industry is Buildings and Property.

  • Is NewLink Genetics (Ebola vaccine) a private or public company?

    NewLink Genetics (Ebola vaccine) is a Private company.

  • What is the current valuation of NewLink Genetics (Ebola vaccine)?

    The current valuation of NewLink Genetics (Ebola vaccine) is 0000.

  • What is NewLink Genetics (Ebola vaccine)’s current revenue?

    The current revenue for NewLink Genetics (Ebola vaccine) is 000000.

  • Who are NewLink Genetics (Ebola vaccine)’s investors?

    Newlink Genetics has invested in NewLink Genetics (Ebola vaccine).

  • When was NewLink Genetics (Ebola vaccine) acquired?

    NewLink Genetics (Ebola vaccine) was acquired on 25-Nov-2014.

  • Who acquired NewLink Genetics (Ebola vaccine)?

    NewLink Genetics (Ebola vaccine) was acquired by Merck & Co..

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »